Can a new drug shield lung cancer patients from Chemo's worst side effects?
NCT ID NCT06370416
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the drug trilaciclib, given before chemotherapy, can prevent bone marrow suppression (low blood cell counts) in people with advanced non-small cell lung cancer. About 40 participants will receive trilaciclib before their platinum-based chemo. The main goal is to see if it reduces severe neutropenia (a dangerous drop in infection-fighting white blood cells).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trilaciclib
What this could lead to
If it works, this could point toward a way to reduce severe side effects from chemotherapy, making treatment more tolerable for lung cancer patients.
What could go wrong
This is a small, early-phase study with only 41 people and no comparison group, so results may not apply broadly. The drug may not reduce side effects as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Tumor Hospital
Zhengzhou, Henan, 450000, China